The burden-of-illness study on osteoporosis in the Slovenian female population

Pharmacy World and Science

Volumn 29, Issue 4, 2007, Pages 404-411

  Dzajkovska, Biljana ^a,b   Wertheimer, Albert I ^c   Mrhar, Ales ^b  

^a Millennium Pharmaceuticals Ltd   (United Kingdom)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

Bone fractures; Burden of illness; Costs; Economics; Health policy; Osteoporosis; Slovenia

Indexed keywords

ALENDRONIC ACID; CALCIUM; ETIDRONIC ACID; RALOXIFENE; SALCATONIN; VITAMIN D;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; FEMALE; FRAGILITY FRACTURE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIP FRACTURE; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MEDICAL EXPERT; POSTMENOPAUSE OSTEOPOROSIS; REHABILITATION CARE; RESOURCE ALLOCATION; SLOVENIA; SPINE FRACTURE; WRIST FRACTURE;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; BONE DENSITY; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; FRACTURES, BONE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HOSPITALIZATION; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SLOVENIA;

EID: 34547569385     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-007-9091-5     Document Type: Article

References (21)

1. WHO Study Group. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis (1994) World Health Organization Technical Report Series 843:5-6
2. Sedrine W, Radican L, Reginster J-Y On conducting burden-of-osteoporosis studies: a review of the core concepts and practical issues. A study carried out under the auspices of a WHO Collaborating Center. Rheumatology 2001;40:7-14
3. Morrison A, Wertheimer AI Types of Pharmacoeconomic Evaluation. In: Morrison A, Wertheimer AI, editors. Pharmacoeconomics. A primer for the pharmaceutical industry. Philadelphia: Temple University; 2002
4. National Osteoporosis Foundation Status Report. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporosis International 1998; 8(S4):S1-S88
5. Ray N, Chan J, Thamer M et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. Journal of Bone and Mineral Research 1997;12(1):24-35
6. Max W, Sinnot P, Kao C et al. The burden of osteoporosis in California, 1998. Osteoporosis International 2002;13:493-500
7. Dolan P, Torgerson DJ The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporosis International 1998;8:611-617
8. Lane A Direct costs of osteoporosis for New Zealand women. PharmacoEconomics 1996;9(3):231-245
9. Rosner A, Grima D, Torrance G et al. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 1998;14(5):559-573
10. IVZ. Ambulantno predpisovanje zdravil v Sloveniji po ATC klasifikaciji v letu; 2003. Available via 〈http://www.ivz.si〉
11. Inštitut za varovanje zdravja Republike Slovenije: Zdravstveni statistični letopis; 2003
12. Melton III L, Thamer M, Ray N et al. Fractures attributable to osteoporosis: report from the national osteoporosis foundation. Journal of Bone and Mineral Research 1997;12(1):16-23
13. http://www.zzzs.si
14. Ferk J Osteoporotični zlomi kolka, zapestja in hrbteničnega vretenca ter stroški zdravljenja Zdravniški Vestnik 2002;71:41-44
15. Koopmanschap AM, Rutten FH A practical guide for calculating indirect costs of disease. PharmacoEconomics 1996;10(5):460-466
16. www.gov.si/zrs/
17. http://www.stat.si
18. De Laet C, Van Hout B, Burger H et al Incremental cost of medical care after hip fracture and first vertebral fracture: The Rotterdam study. Osteoporosis International 1999;10(1):66-72
19. Vestergaard P, Rejnmark L, Mosekilde L Hip fracture prevention. Cost-effective strategies. Pharmacoeconomics 2001;19(5Pt1):449-468
20. Kanis J, Oden A, Johnell O et al The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporosis International 2001;12:417-427
21. Ankjaer-Jensen A, Johnell O Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporosis International 1996;6:265-275